Biotechnology

FDA Grants Orphan Drug Designation to 9MW3011

SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...

2024-02-20 22:00 1142

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...

2024-02-20 21:00 2697

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

HEFEI, China, Feb. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, autoimmune diseases, and inflammation, through targeted protein degradation technology, today announced th...

2024-02-20 20:00 1006

Origin Agritech Regains Compliance with Nasdaq Listing Standards

BEIJING, Feb. 20, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced that it has regained compliance with Nasdaq's market value of listed securities requirement as set forth in Listing Rule 5550(...

2024-02-20 20:00 2300

HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment

At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...

2024-02-19 20:18 1562

Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.

WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused byND4 mutati...

2024-02-19 19:30 1097

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...

2024-02-19 09:00 3000

Everest Medicines Announces Termination of Collaboration Agreements with Providence

-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...

2024-02-19 08:20 1463

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...

2024-02-18 20:50 1703

New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC

 - A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. ...

2024-02-16 22:03 2194

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be ...

2024-02-15 17:05 1696

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license...

2024-02-15 16:05 1670

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...

2024-02-15 11:37 1271

YS Biopharma Announces Appointment of New Directors

GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...

2024-02-14 20:50 3335

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...

2024-02-14 08:07 3527

Ajinomoto Co. Launches Silicon Valley CVC HQ to Grow U.S. Investments, Adds New Portfolios

TOKYO, Feb. 13, 2024 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co."), the Japan-based multinational corporation covering food, healthcare and electronic materials, and built on "AminoScience," (*) has expanded its corporate venture capital (CVC) arm with new U.S. headquarters to grow its in...

2024-02-13 14:00 1387

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive  Asset Purchase Agreement datedFebruary 11th, 2024 to acquire the entire portfolio of discovery, preclinical and cli...

2024-02-13 03:26 3667

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

* Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in space * Dr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory Board ...

2024-02-09 22:44 2467

YS Biopharma Announces US$40 Million Private Placement Financing

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and th...

2024-02-09 19:30 6005

UFC WORLD CHAMPION JON JONES, LIFECYKEL LABS, CANTERBURY-BANKSTOWN BULLDOGS AND BETTER BREATHING DEVICES HOST ELITE PERFORMANCE/TRAINING DAY

SYDNEY, Feb. 9, 2024 /PRNewswire/ -- Jon Jones, UFC world champion and arguably the best MMA fighter to have ever existed is touringAustralia and has teamed up with Lifecykel Labs to host and facilitate a best-in-class performance training day which was held at the Canterbury-Bankstown Bulldogs h...

2024-02-09 18:09 2964
1 ... 567891011 ... 275

Week's Top Stories